Lambert‐Eaton Myasthenic Syndrome: A Review

• Matsumoto Hideyuki

  Department of Neurology, Japanese Red Cross Medical Center

• Ugawa Yoshikazu

  Department of Neurology, School of Medicine, Fukushima Medical University

書誌事項

タイトル別名

• Lambert-Eaton Myasthenic Syndrome: A Review

抄録

Lambert-Eaton myasthenic syndrome (LEMS) is an auto-immune disorder caused by neuromuscular transmission failure, and is a representative pre-neuromuscular junctional disorder. The auto-immune antibody is anti-P/Q-type voltage-gated calcium channel (P/Q-type VGCC) antibody detected in approximately 80 to 90% of LEMS patients. Approximately 60% of LEMS patients have small cell lung cancer (SCLC), approximately 10% of patients have other malignant tumors, and the remaining 30% have no malignancy. Thus, the therapeutic strategy for LEMS depends on the presence of a malignant tumor. LEMS with a malignant tumor is also considered to be a representative paraneoplastic neurological syndrome. Recently, new chemotherapeutic drugs for malignant tumors including SCLC have been developed. In cases with no malignancy, several new immune-mediated therapies have become available. Therefore, we can expect improved therapeutic responses for this disorder.

収録刊行物

• Journal of General and Family Medicine

  Journal of General and Family Medicine 17 (2), 138-143, 2016

  一般社団法人 日本プライマリ・ケア連合学会

キーワード

• Lambert-Eaton myasthenic syndrome (LEMS)
• anti-P/Q-type voltage-gated calcium channel (P/Q-type VGCC) antibody
• small cell lung cancer (SCLC)
• paraneoplastic neurological syndrome
• repetitive nerve stimulation test

詳細情報

• CRID: 1390282680740609920
• NII論文ID: 130005158235
• DOI: 10.14442/jgfm.17.2_138
• ISSN: 21897948
• ISSN: 21896577
• Web Site: https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.14442%2Fjgfm.17.2_138
• Web Site: https://onlinelibrary.wiley.com/doi/pdf/10.14442/jgfm.17.2_138
• 本文言語コード: en
• データソース種別:
  • JaLC
  • Crossref
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可